News Capricor’s DMD hope still strong, as it shares financials Capricor shares second quarter financials as FDA reconsiders BLA for DMD therapy deramiocel.
News FDA advisors vote no to Capricor's DMD therapy FDA advisors voted that Capricor has not shown efficacy for deramiocel in Duchenne muscular dystrophy, due to altered endpoints in its main trial.
News Capricor sues partner Nippon Shinyaku in DMD therapy spat Capricor has filed a lawsuit seeking to split from its commercial partner for Duchenne muscular dystrophy therapy, deramiocel, in the US.
News Capricor files cell therapy for DMD cardiomyopathy with FDA Capricor completes its US filing for deramiocel, vying to become the first FDA-approved therapy for cardiomyopathy in Duchenne muscular dystrophy.
News Capricor preps phase 3 for Duchenne cell therapy as it seeks... Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease pro
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
